TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10925450

Group type: EXPERIMENTAL
Intervention: HPV positive tumour
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normal epithelium controls
Number of subjects: 21
Study: 8818846

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg) administered as a single dose 12, 24 or 48 h before tympanostomy tubes insertion in 17 children with secretory otitis media
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on day 1, 5 mg/kg on days 2-5) administered once daily for 5 days in 12 children with acute otitis media
Number of subjects: 29
Study: 1735260

Group type: EXPERIMENTAL
Intervention: NPSV with BIPAP device
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NPSV with Bird 6400ST device
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 8
Study: 6489326

Group type: EXPERIMENTAL
Intervention: Oral administration of ciprofloxacin (250 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous administration of ciprofloxacin (100 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Both oral and intravenous administration of ciprofloxacin
Number of subjects: 6
Study: 2868030

Group type: EXPERIMENTAL
Intervention: Propranolol (full beta-receptor blockade)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diltiazem, 240 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of propranolol and diltiazem, 240 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of propranolol and diltiazem, 360 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination therapy (low dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination therapy (high dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall clinical response
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Higher dose diltiazem combination
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Left ventricular function (radionuclide ventriculography)
Number of subjects: 24
Study: 29852309

Group type: EXPERIMENTAL
Intervention: CBT for SUD and anxiety disorders (CALM ARC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 27999367

Group type: EXPERIMENTAL
Intervention: Sleep Restriction (SR) - 4 hours time in bed (04:00-08:00)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Total Sleep Deprivation (TSD) - 0 hours time in bed
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Recovery after TSD
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Recovery after SR
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Men during late-night hours and the day following sleep loss
Number of subjects: 66
Study: 24670079

Group type: EXPERIMENTAL
Intervention: Multidisciplinary inpatient treatment at the Dutch Asthma Center in Davos, Switzerland for six weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multidisciplinary treatment at the outpatient clinic of the Wilhelmina Children's Hospital, Utrecht, the Netherlands for six weeks
Number of subjects: 0
Study: 22383237

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.1‐mmol/kg)
Number of subjects: 114
Study: 20858263

Group type: EXPERIMENTAL
Intervention: Elective percutaneous coronary intervention of the chronic total occlusion within seven days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 300
Study: 19071983

Group type: EXPERIMENTAL
Intervention: Adolescent language during brief motivational interventions
Number of subjects: 54
Study: 16026898

Group type: EXPERIMENTAL
Intervention: Antimicrobial central venous catheter (CVC) made of polyurethane integrated with silver, platinum and carbon black (Vantex)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Control catheter
Number of subjects: 539
Study: 14514946

Group type: COMPARATOR
Intervention: DQB1*05 allele
Number of subjects: 38

Group type: COMPARATOR
Intervention: DQB1*02 allele
Number of subjects: 38

Group type: COMPARATOR
Intervention: DQB1*03,*04,*06 alleles
Number of subjects: 38
Study: 10566642

Group type: COMPARATOR
Intervention: 131I alone (28 patients)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 131I plus pretreatment with methimazole (30 mg/day; 23 patients)
Number of subjects: 51
Study: 8923753

Group type: EXPERIMENTAL
Intervention: Presence of extra visual‐spatial cues
Number of subjects: 80

Group type: COMPARATOR
Intervention: Absence of extra visual‐spatial cues
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Boys with extra cues
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Girls with extra cues
Number of subjects: 80

Group type: COMPARATOR
Intervention: Boys and girls without extra cues
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Block design test
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reduced KAT cues
Number of subjects: 80
Study: 1829901

Group type: EXPERIMENTAL
Intervention: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under low potassium diet (LK)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under low salt diet (LS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ser‐Tyr28 human ANH infusion at 0.5 pmol/kg/min for 2 hours under high potassium diet (HK)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 6347578

Group type: EXPERIMENTAL
Intervention: Intensive patient education (group A)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 77
Study: 31591119

Group type: COMPARATOR
Intervention: Nafithromycin (100 to 1200 mg) under fasted or fed condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nafithromycin (400 and 800 mg) under fed condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nafithromycin (600, 800, or 1000 mg) once daily for 7 days under fed condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nafithromycin (600 mg and 800 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nafithromycin (1000 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nafithromycin (single and multiple dosing)
Number of subjects: 0
Study: 28605411

Group type: EXPERIMENTAL
Intervention: Very low nicotine content (VLNC) cigarettes; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statistical methods including inverse probability of compliance weighted (IPCW) estimators; specific details not mentioned.
Number of subjects: 0
Study: 26178779

Group type: EXPERIMENTAL
Intervention: Exercise Vital Sign (EVS) questionnaire
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stanford Brief Activity Survey (SBAS) questionnaire
Number of subjects: 30
Study: 24583274

Group type: EXPERIMENTAL
Intervention: Integrated intervention (n=48): six individual treatment visits plus eight weeks of nicotine patch therapy integrated with binge drinking intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard treatment (n=47): six individual treatment visits plus eight weeks of nicotine patch therapy
Number of subjects: 95
Study: 21944429

Group type: EXPERIMENTAL
Intervention: Interpersonal competence
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Adaptive behaviour
Number of subjects: 96
Study: 20076935

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy (LA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended radical lymphadenectomy
Number of subjects: 0
Study: 17663100

Group type: EXPERIMENTAL
Intervention: Acupuncture at Fengchi (GB 20), Quchi (LI 11), Neiguan (PC 6), Zusanli (ST 36), Fenglong (ST 40), Taicehong (LR 3) and oral administration of Captoril
Number of subjects: 60

Group type: COMPARATOR
Intervention: Captoril
Number of subjects: 60
Study: 16102099

Group type: EXPERIMENTAL
Intervention: rFVIIa (80 microg kg(‐1))
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: rFVIIa (160 microg kg(‐1))
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 11816920

Group type: EXPERIMENTAL
Intervention: Follow‐up home visits by a physician (INT1‐HVP)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Instruction by a physiotherapist in their home (INT2‐PI)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Standard aftercare (control)
Number of subjects: 155
Study: 9222075

Group type: EXPERIMENTAL
Intervention: Trovafloxacin 200 mg in the morning and placebo in the evening (group A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo twice daily (group B)
Number of subjects: 12
Study: 7609517

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amlodipine 10 mg once daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 80
Study: 3539691

Group type: EXPERIMENTAL
Intervention: 6 hours of bed rest
Number of subjects: 40

Group type: COMPARATOR
Intervention: 24 hours of bed rest
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follow-up ultrasound at 7 days
Number of subjects: 40
Study: 28793989

Group type: EXPERIMENTAL
Intervention: Enteral tube feeding for ≥7 days in addition to standard care (intravenous rehydration and antiemetic treatment)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard care alone (intravenous rehydration and antiemetic treatment)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Enteral tube feeding
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 116
Study: 25520044

Group type: EXPERIMENTAL
Intervention: Valid cue condition (subliminal cue presented at the same side as the target)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Invalid cue condition (subliminal cue presented on the opposite side of the target)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral condition (not explicitly defined but mentioned in Experiment 2)
Number of subjects: 0
Study: 22850935

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D(3) supplementation (20,000 IU weekly)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 20950168

Group type: EXPERIMENTAL
Intervention: Anodyne® treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: HealthLight™ treatment
Number of subjects: 25
Study: 19432693

Group type: EXPERIMENTAL
Intervention: Cool-temperature dialysate (HD(35), 35 degrees C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard-temperature dialysate (HD(37), 37 degrees C)
Number of subjects: 10
Study: 17088127

Group type: EXPERIMENTAL
Intervention: Mild to moderate asthma
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Budesonide or nedocromil and placebo
Number of subjects: 1041
Study: 15069115

Group type: EXPERIMENTAL
Intervention: Radiology intervention (immediate reading of mammograms)
Number of subjects: 8543

Group type: EXPERIMENTAL
Intervention: Educational intervention (teaching skills to cope with anxiety)
Number of subjects: 8543

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 8543

Group type: COMPARATOR
Intervention: Women with normal mammograms
Number of subjects: 8543

Group type: EXPERIMENTAL
Intervention: Women with false-positive mammograms (3 months after mammogram)
Number of subjects: 8543
Study: 11309768

Group type: EXPERIMENTAL
Intervention: Lumpectomy with local irradiation
Number of subjects: 1039

Group type: COMPARATOR
Intervention: Lumpectomy without local irradiation
Number of subjects: 1039
Study: 9441287

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (Ch.T. without urine abnormalities)
Number of subjects: 42
Study: 7950228

Group type: EXPERIMENTAL
Intervention: Puji ointment (PJO)
Number of subjects: 628
Study: 3586248

Group type: EXPERIMENTAL
Intervention: Flight nurse/flight physician team
Number of subjects: 574

Group type: COMPARATOR
Intervention: Flight nurse/flight paramedic team
Number of subjects: 574
Study: 29602557

Group type: EXPERIMENTAL
Intervention: Cholecystectomy after mild gallstone pancreatitis
Number of subjects: 262
Study: 26889617

Group type: EXPERIMENTAL
Intervention: Cabbage Leaf Wraps (CLWs) for 4 weeks (daily for at least 2 hours)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cabbage Leaf Wraps (CLWs) for 4 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Topical Pain Gel (TPG) (10 mg diclofenac/g, at least once daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 81
Study: 26201153

Group type: EXPERIMENTAL
Intervention: Multi-use catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-use catheters
Number of subjects: 0
Study: 23744798

Group type: EXPERIMENTAL
Intervention: Nicotine (gum, 6 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 21294143

Group type: EXPERIMENTAL
Intervention: Tenofovir
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 19057883

Group type: EXPERIMENTAL
Intervention: DMARD or TNF-alpha-inhibitors
Number of subjects: 192
Study: 16371605

Group type: EXPERIMENTAL
Intervention: BIS-directed group (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 50
Study: 15327421

Group type: EXPERIMENTAL
Intervention: 0.25 mmol/L dMg, 1.25 mmol/L dCa (group IV)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 0.75 mmol/L dMg, 1.25 mmol/L dCa
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.25 mmol/L dMg, 1.75 mmol/L dCa (group II)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.75 mmol/L dMg, 1.75 mmol/L dCa (group I)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 0.75 mmol/L dMg, 1.25 mmol/L dCa (group III)
Number of subjects: 22
Study: 11207080

Group type: EXPERIMENTAL
Intervention: Non-ionic contrast media (Group I)
Number of subjects: 3990

Group type: COMPARATOR
Intervention: Ionic Ioxaglate (Group II)
Number of subjects: 3990
Study: 7624818

Group type: EXPERIMENTAL
Intervention: Video viewing
Number of subjects: 1653

Group type: EXPERIMENTAL
Intervention: Video viewing followed by interactive group session
Number of subjects: 1653

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1653
Study: 2754052

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐nl, 5 million units, subcutaneously daily for 2 weeks then twice weekly for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isotretinoin, 1 mg/kg by mouth daily for 6 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination treatment: interferon therapy three times weekly in combination with daily isotretinoin for 6 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Sequential treatment: those whose clearing was incomplete with interferon alone were switched to interferon three times weekly for 6 weeks
Number of subjects: 17
Study: 792993

Group type: EXPERIMENTAL
Intervention: Salbutamol tablets (4 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of salbutamol tablets and aerosols
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Salbutamol aerosol (100 mug)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combined active treatment
Number of subjects: 14
Study: 31412579

Group type: EXPERIMENTAL
Intervention: Nutrition subsidy with specific target of anemia reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nutrition subsidy with general target of malnutrition reduction
Number of subjects: 0
Study: 27452896

Group type: EXPERIMENTAL
Intervention: Standard SGI (12 sessions, twice weekly)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham irradiation (control group)
Number of subjects: 44
Study: 26090394

Group type: EXPERIMENTAL
Intervention: Intermittent warm blood cardioplegia (IWC)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Intermittent cold blood cardioplegia (ICC)
Number of subjects: 68
Study: 25447201

Group type: EXPERIMENTAL
Intervention: Probiotics administered to 5 infants
Number of subjects: 43

Group type: COMPARATOR
Intervention: No probiotics administered to 38 infants
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Post-trial testing
Number of subjects: 43
Study: 22549432

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2.4 gm/day
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19464865

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (30 min treadmill exercise, 3 times per week for 6 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 40
Study: 17988315

Group type: EXPERIMENTAL
Intervention: Racism condition (history lessons including information about racism experienced by African Americans)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control condition (history lessons that omitted information about racism)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Racism condition
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 117
Study: 16128502

Group type: EXPERIMENTAL
Intervention: Software-based telephone counseling
Number of subjects: 366

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 366
Study: 12139206

Group type: EXPERIMENTAL
Intervention: Trospium chloride (20 mg twice daily)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 517
Study: 9499701

Group type: EXPERIMENTAL
Intervention: Significant IRS at Session 1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IRS stability
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Participants with significant IRS at Session 1
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Between-session IRS (trait-IRS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Within-session IRS (state-IRS)
Number of subjects: 48
Study: 8942402

Group type: EXPERIMENTAL
Intervention: low‐dose phentolamine
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: high‐dose phentolamine
Number of subjects: 14

Group type: COMPARATOR
Intervention: control (no drug)
Number of subjects: 14
Study: 1749945

Group type: EXPERIMENTAL
Intervention: 50 mg gold sodium thiomalate (GST) administered intramuscularly for 12 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: 15 mg methotrexate (MTX) administered intramuscularly for 12 months
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 50 mg gold sodium thiomalate (GST)
Number of subjects: 102

Group type: COMPARATOR
Intervention: 15 mg methotrexate (MTX)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study: 7200736

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion (100‐150 ng/kg/minute)
Number of subjects: 0
Study: 30586755

Group type: EXPERIMENTAL
Intervention: Impella device
Number of subjects: 372

Group type: COMPARATOR
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 372
Study: 28287799

Group type: EXPERIMENTAL
Intervention: Personalized normative feedback (PNF) intervention
Number of subjects: 784

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 784
Study: 26867477

Group type: EXPERIMENTAL
Intervention: Mallinckrodt tube (ML)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Intersurgical tube (IS)
Number of subjects: 26
Study: 24559754

Group type: EXPERIMENTAL
Intervention: Tracheostomy placement
Number of subjects: 51
Study: 20963411

Group type: EXPERIMENTAL
Intervention: Vaccination with WT1-, Pr3-, and MUC1-derived peptides combined with CpG7909 and MontanideISA51
Number of subjects: 9
Study: 19862403

Group type: COMPARATOR
Intervention: Aegis + control (phosphoric acid etch only)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aegis + Optibond Solo Plus
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Various sealants and adhesive agents
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fissure morphology
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Microleakage and penetrability correlation
Number of subjects: 90
Study: 18426091

Group type: EXPERIMENTAL
Intervention: Sub-maximum exercise at 1,700 meters altitude (EC)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sub-maximum exercise at sea level (MSL)
Number of subjects: 9
Study: 15687413

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study: 11495449

Group type: EXPERIMENTAL
Intervention: Mycobacterium habana vaccine (1.5 mg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Mycobacterium habana vaccine
Number of subjects: 67
Study: 9743309

Group type: EXPERIMENTAL
Intervention: VIP (four cycles of etoposide, ifosfamide, cisplatin)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BEP (four cycles of bleomycin, etoposide, cisplatin)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: VIP
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BEP
Number of subjects: 84
Study: 7594346

Group type: EXPERIMENTAL
Intervention: Half-dose q.d. (30 mg/day)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Weekend full-dose (30 mg on weekends)
Number of subjects: 71
Study: 2643641

Group type: EXPERIMENTAL
Intervention: Karaya gum patches containing salicylic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patches (without salicylic acid)
Number of subjects: 0
Study: 1101595

Group type: EXPERIMENTAL
Intervention: Infraclavicular puncture of the subclavian vein
Number of subjects: 125

Group type: COMPARATOR
Intervention: Basilic vein catheterization
Number of subjects: 125
Study: 31876991

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 51)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (n = 53)
Number of subjects: 104
Study: 31088569

Group type: EXPERIMENTAL
Intervention: CHW-led multimedia intervention
Number of subjects: 408

Group type: COMPARATOR
Intervention: Wait-list control arm
Number of subjects: 408
Study: 27614662

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) with adjunctive Memory Support Intervention (CT + Memory Support)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CT-as-usual
Number of subjects: 48
Study: 25222484

Group type: EXPERIMENTAL
Intervention: Therapist Brief Intervention (TBI)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Computer Brief Intervention (CBI)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1053
Study: 23219236

Group type: EXPERIMENTAL
Intervention: Mtb72F/AS02
Number of subjects: 38

Group type: COMPARATOR
Intervention: AS02
Number of subjects: 38
Study: 21762179

Group type: EXPERIMENTAL
Intervention: Ethanol (0.5 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fruit juice (control)
Number of subjects: 64